Filing Flows › Longeveron (LGVN) › Q2 2025
Longeveron (LGVN) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
Longeveron (LGVN) reported revenue of $316K for the second quarter 2025 (Q2 2025), -32% from a year earlier and -17% from the quarter before.
Longeveron, Q2 2025: revenue $316K (-32% year over year), net loss $5.0M, operating cash flow −$3.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $316K | -17% | -32% |
| Operating profit | −$5.4M | — | — |
| Net earnings | −$5.0M | — | — |
| Operating cash flow | −$3.6M | — | — |
What changed
Revenue was $316K in Q2 2025, down 32% year over year and down 17% from the previous quarter. Clinical Trial Revenue was the largest line at 94% of revenue. Contract Manufacturing Lease Revenue lost $153K year over year (down 96%), 101% of the total change.
Gross margin was 46.2%, down 27.3 points from a year earlier. Operating costs exceeded revenue by $5.4M, an operating margin of -1707.9%. Operating expenses grew 44% against a revenue fall of 32%. The fastest-growing cost line was Research & development (+72%). The quarter ended with a net loss of $5.0M, wider than the previous quarter's $5.0M loss.
Operating cash flow was −$3.6M. Non-cash charges added back $263K of depreciation and amortization and $513K of share-based compensation. Working capital and other items added $655K. Capital expenditures of $161K exceeded it, leaving free cash flow of −$3.8M.
Questions
What was Longeveron's revenue in the second quarter 2025?
Longeveron (LGVN) reported revenue of $316K for the second quarter 2025 (Q2 2025), -32% from a year earlier and -17% from the quarter before.
Source: Longeveron 10-Q on SEC EDGAR.